These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Group sequential clinical trials for longitudinal data with analyses using summary statistics. Kittelson JM; Sharples K; Emerson SS Stat Med; 2005 Aug; 24(16):2457-75. PubMed ID: 15977295 [TBL] [Abstract][Full Text] [Related]
44. Can clinical trials requiring frequent participant contact be conducted over the Internet? Results from an online randomized controlled trial evaluating a topical ointment for herpes labialis. Formica M; Kabbara K; Clark R; McAlindon T J Med Internet Res; 2004 Feb; 6(1):e6. PubMed ID: 15111272 [TBL] [Abstract][Full Text] [Related]
45. The data monitoring experience in the MOXCON trial. Pocock S; Wilhelmsen L; Dickstein K; Francis G; Wittes J Eur Heart J; 2004 Nov; 25(22):1974-8. PubMed ID: 15541832 [TBL] [Abstract][Full Text] [Related]
46. The WHO International Clinical Trials Registry Platform: relevance to the Indian register of clinical trials. Tharyan P Natl Med J India; 2006; 19(3):161-4. PubMed ID: 16836269 [No Abstract] [Full Text] [Related]
47. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Lachin JM Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730 [TBL] [Abstract][Full Text] [Related]
48. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472 [TBL] [Abstract][Full Text] [Related]
49. Methods for mid-course corrections in clinical trials with survival outcomes. Cook TD Stat Med; 2003 Nov; 22(22):3431-47. PubMed ID: 14601011 [TBL] [Abstract][Full Text] [Related]
50. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Whitehead J; Matsushita T Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099 [TBL] [Abstract][Full Text] [Related]
51. Who's minding the data? Data Monitoring Committees in clinical cancer trials. Keating P; Cambrosio A Sociol Health Illn; 2009 Apr; 31(3):325-42. PubMed ID: 19055588 [TBL] [Abstract][Full Text] [Related]
54. Fallacies in clinical cardiovascular trials. Swedberg K Heart; 2009 Sep; 95(17):1464-8. PubMed ID: 19684197 [No Abstract] [Full Text] [Related]
55. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting? Bryant J Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728 [TBL] [Abstract][Full Text] [Related]
56. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods. Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243 [TBL] [Abstract][Full Text] [Related]
57. Risks in Randomized Controlled Trials: Role of Interim Analysis and Data Monitoring Committee. Naqvi HA J Coll Physicians Surg Pak; 2015 Aug; 25(8):557-9. PubMed ID: 26305298 [No Abstract] [Full Text] [Related]
58. Keeping patients safe while avoiding bias in randomised trials. Freemantle N; Van de Werf F BMJ; 2012 May; 344():e3297. PubMed ID: 22586233 [No Abstract] [Full Text] [Related]
59. International differences in treatment effects in cardiovascular clinical trials. O'Shea JC; Califf RM Am Heart J; 2001 May; 141(5):875-80. PubMed ID: 11320382 [No Abstract] [Full Text] [Related]